OB Nest; Redefining Continuity of Care for Expectant Mothers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02082275 |
Recruitment Status :
Completed
First Posted : March 10, 2014
Last Update Posted : January 8, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pregnancy | Other: OB Nest | Not Applicable |
OB Nest is a model designed to promote increased patient-centered care during pregnancy. OB Nest care will allow for more flexibility, decrease interruptions to your productivity, while continuing to maintain safety for you and your infant. This model of care is anticipated to allow you more access to your health care team during your pregnancy.
This study will compare OB Nest, a new model of prenatal care, to the existing traditional model of prenatal care. The plan is to have about 300 low-risk mothers take part in this study. Eligible patients will be randomized to one of two groups; The Traditional Prenatal care Group or the OB Nest Group. Mothers will have an equal chance of being assigned to the OB Nest group. Mothers randomized to the OB Nest intervention will be assigned to a nursing care team comprised of one to three nurses and see their initial eleven planned appointments with their provider reduced to six. Mothers will still be able to request additional in-office visits with their provider and/or the provider require additional in-office visits to monitor mother and infants safety/care.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Official Title: | Implementation and Evaluation of the OB Nest Project at the Point of Care: Redefining Continuity of Care for Expectant Mothers. |
Study Start Date : | February 2014 |
Actual Primary Completion Date : | October 2015 |
Actual Study Completion Date : | November 2015 |
Arm | Intervention/treatment |
---|---|
Experimental: OB Nest
OB Nest is designed to reduce the number of pre-planned visits with their OB provider and replace the in-clinic visits with a direct and constant support from an assigned nursing team. OB Nest will empower moms-to-be to take ownership of their prenatal care by providing a wealth of resources.
|
Other: OB Nest
|
No Intervention: Traditional Prenatal care
Traditional prenatal visits in clinic with OB providers.
|
- Expectant mothers satisfaction of prenatal care [ Time Frame: 36 weeks ]At 36 weeks the expectant mother will complete a survey that assessed their satisfaction of the prenatal care received using a validated scale.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 18+ years of age
- Documented gestational age less than 13 weeks.
- Pregnancy documented as low risk (See high risk exclusion criteria below)
- Able to read and understand English
- Able to provide informed consent (i.e. no impairments or barriers)
Exclusion Criteria:
Clinical judgment that determines that the pregnancy is at high risk for complications.
Any of the following high risk factors would disqualify the mother for the study:
- Severe hypertension (>160/110)
- Possible ectopic
- Congenital adrenal hypertension
- Prior PE/DVT/stroke
- Anticoagulation during prior pregnancy (e.g. antiphospholipid antibody syndrome)
- Prosthetic heart valve (non-bio)
- Pulmonary hypertension
- Mothers currently taking Immunosuppressants, Prednisone > 10mg per day, antipsychotic (e.g. lithium, Haldol, Zyprexa), chemotherapy
- Recurrent pregnancy loss (>2 losses)
- Current maternal malignancy
- Prior myocardial infarction/cardiomyopathy
- Bio-prosthetic heart valves
- Marfan syndrome
- Active liver disease (e.g. hepatitis)
- Congenital heart disease
- Coagulopathies including thrombophilias and bleeding disorders.
- Pre-existing diabetes
- Genetic disease/CF testing/anomalies in prior child
- Incompetent cervix (prior cerclage)
- Triplets or quads diagnosed by REI or ultrasound.
- Isoimmunization (Rh, Kell, etc.)
- History of transplant or currently on Dialysis
- Recurrent pregnancy loss (antiphospholipid antibody syndrome or collagen vascular disease)
- Chronic hypertension
- Prior 2nd or 3rd trimester loss
- HIV
- Inflammatory bowel disease
- Asthma and currently on steroid to control disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02082275
United States, Minnesota | |
Mayo Clinic in Rochester | |
Rochester, Minnesota, United States, 55905 |
Principal Investigator: | Abimbola Famuyide, MBBS | Mayo Clinic |
Responsible Party: | Abimbola Famuyide, Associate Professor of Obstetrics-Gynecology, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT02082275 |
Other Study ID Numbers: |
13-009513 |
First Posted: | March 10, 2014 Key Record Dates |
Last Update Posted: | January 8, 2016 |
Last Verified: | January 2016 |
Prenatal Care Obstetrics |